No annual revenue total was found in Cadrenal Therapeutics, Inc.'s SEC filings.
Cadrenal Therapeutics, Inc. (CVKD) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$12.6 million.
Revenue
—
Net income (TTM)
$-11.54M
+18.2% vs year-ago TTM
Operating cash flow (TTM)
$-10.16M
+12.9% vs year-ago TTM
Free cash flow
$-12.61M
-71.2% vs prior year
EPS (TTM)
$-4.87
+43.6% vs year-ago TTM
Dividend per share
$16.50
+0.0% vs prior year
Shares outstanding
2.51M
+33.4% vs prior year
Net cash
$8.38M
FY 2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CVKD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ponte Vedra, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1937993
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$13.5M | -$11.0M | -$7.6M | -$2.7M |
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M |
| Diluted EPS | -$6.64 | -$8.73 | -$9.29 | -$0.85 |
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Free cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Total assets | $4.3M | $10.1M | $8.5M | $778,174 |
| Total liabilities | $1.6M | $2.7M | $826,875 | $6.3M |
| Stockholders' equity | $2.7M | $7.4M | $7.7M | -$5.6M |
| Cash and investments | $4.0M | $10.0M | $8.4M | $32,586 |
| Total debt | — | — | $21,350 | $43,638 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
All 277 Cadrenal Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.